Time to occurrence of MI according to baseline hematocrit status in males. Canagliflozin reduced the risk of MI in patients with anemia (A) (HR, 0.53; 95% CI, 0.34–0.83). In patients with normal hematocrit (B), the treatment effect was neutral (HR, 1.00; 95% CI, 0.80–1.25). In patients with erythrocytosis (C), canagliflozin showed a trend toward increased risk of MI (HR, 1.77; 95% CI, 0.76–4.13). The graphs were truncated at 4 years. Anemia was defined as a hematocrit level of <39%; erythrocytosis was defined as a hematocrit level of >49%.